~12

%-I:1#. AJiIil~

liI~t~k~*~~4rn~~#ft~~

20

- '1"t~nE11~m (Metabolic syndrome) 2.~B

1i:~~1r~UWzJE~JU: ' § WJ1H\t{IOO~Jl~f.Hi:

~~~~~JE~'~M~~~*~~~~~ (US

National Institutes of Health) '~ll.J;HjJ7Rm$flM

(International Diabetes Federation, IDF) Wt!t:n.~~~Jl~ (World Health Organization, WHO) 0

1t<t1~~.J7Rm$flM (International Diabetes Fed­

eration, IDF) ~t1i:~~1*~ZJE~L (~-) ,~~,mJ't1fJMg~ij~1W ' t!P:!1'J'I1:!lIIII:*::fjj 94 051 '~'I1:!lIIII:*::fjj 80 051 0 llt9i-l£rJ'Ji[9JJiI!l-=f$J'tfFm~$-=JJit!PfBtJE~~1i:~~1*~ , ~~Mr'i?J=:Mttill:Jli ' t!PIfo.$'=:Mttill:Jli:*::fjj I50mg/dL ; 1£1;r'i?Jm~mm~W~~'Wr'i?Jm~mm~W~.l£

:!1'J'I1:;J \:fjj 40 mg/dL ' ~'I1:J{rj;J \:fjj 50 mg/dL ; r'i?JIfo.IE ' t!PJL'ft~~~IE:*::fjj 130 mID Hg , JL,!it~H~1E

:*::fjj 85 mID Hg ; r'i?J~JMIfo.. (fasting plasma glu­

cose, FPG) 't!Pf~~JMIfo..:*::fjj100 mg/dL 0

='1"t~nE11~m2.)ntfJl£+1f.WJR1fY~i¥J)dm~ 1i'1i:~~{~~.!J

~{IOO~~1ij , ffifE~4-~P1f1JVpAfBt~IJTI±lJ't1f1i:~

~~~z~~'D~~c~~~~~fiz*mo

l£~~'R~~~~Z~fi~~IT1f=:~nB~

~-Mz~1f.AmM'H:*:3~~~*.~1JT

~ 0 1'£~~ , 1i:~~{~~z~1TW{IOOApJT1~1f~,ijl~i¥Jffi~I1:'~1fli51Z-i¥J~~A1fR~~~

~zm'WJJ ' H~fr5.mi¥J:!1'J'I1:W~'I1:~~1T~1tr'i?J1±l-= ' =:1'& 0 ~ffij1i:~~{t*~zf~~~1ftlafnM

z.J7Rm~~'~~1t~~m-=~.J7Rm,~~

~~*mW~3*mz~~ ' -~Xfi~ X~~

~ (syndrome X) W~~~~]JJt~{~~ (insulin

resistance syndrome ) '§WJcm1tTE87(~~51Z(~

ftWtlJfll*3I¥rj&~ 0 1i:~~{~~1t<-~i¥J~r

J{]-diTfJ~J't1fJM$ij~ij* ' ~~~~lUJt'11: ' Ifo.Mftr'i?J -'-~rfif.T' ~~W~.ftr'i?J ' {£I;mltij~m~W~

.ftr'i?J''=:Mttill:Jliftr'i?JWr'i?Jmltmm~w~.

~{£I; 0

- , 1"t~nE~m2.~JJXI2SI~1. Ifo.ij~1f {i:~~m (Dyslipidemia )

Ifo.n~1f{i:~~m ' r'i?JIfo.IEW$ra'~ij~ij*~1'@

{~~~5*5~lif{t ' ~JL,mWJL'Ifo.'f*mZ:±1!I '~~~~~R~~~~z~~~l!Iz-o-~m

fizIfo.m1fR~~m~m=:Mttill:Jlii¥Jftr'i?J'r'i?J

mltm.~W~.i¥J~fiWfimltm.~W~.

i¥Jftr'i?J 0 ~~f~1±l ' r'i?J=:Mttill:JIiIfo.~1ti:Jr~~

~~mM'~~~~III~~~••tt~mi¥J:±~

JJj{rzg 0 ij~IWWIfo.n~1f{i:~~m ' g~~Ifo.fi~~L ' E13:fjjij~lW~zn~JW~Jl.pJT517MziJff.n~JWM

(free fatty acid, FFA) 1t!t1Ja ' I!Iffij{~~~~~~*mM'11: ' H~1~JffIJi$=:Mttill:JIiW~{£I;mltn~. ~ (very low density lipoprotein, VLDL)

i¥J~~!t1Ja 0 Ifo.91!$ =:Mttr83Ii!t1Ja1t{~1~m~lI!X{tJJ£~ , ~ffij{~~{tlEtJ!t1Ja 0 ~~~f~

I±l ' r'i?J'=:Mttill:JIiWr'i?Jm~n~.~ (high density

lipoprotein, HDL) Z ~{£I;~W1m~*~llM'11:1fII 0 ~ffijn~JW*1l~pJT517£'Z FFA!t1Ja ' 1t{~*1l.f&-=f (tissue factor, TF) W.*iJJJJj{~fr5~1!IJ*1j~~

(plasminogen activator inhibitor-l , PAl-I) !t1Ja 'ffij{~1~Ifo./N&IiE~ftr'i?J ' ~ffij{'@{~Ifo.fiz~~ 0

2. r'i?JIfo.IE (Hypertension)

R~~~~Z~rzgL'r'i?JIfo.lEm~~~~rzg

*Z- 0 ij~IW'I1:r'i?JIfo.IEi¥J~~~f~z-~WIJi$

~i¥JIJ&~~~!t1Ja ' HmJff!!9H1~Z~:S:!t:*: ' ~ffij

~3&Ifo.IEi¥Jftr'i?J 0 epq~jfJIfo.lEz~~~~t!P~

W~-Ifo.'f~~~~~~ (renin-angiotensin system,

RAS) 0 l£ij~lWzW®§~~$ , ~n~JWW~Fn~JW~Jl~ZW~-Ifo.'f~~~~q~~~~~~rtJL~

~ 0 )(IU~ I±l ' W~ (rennin ) 'Ifo. 'f ~~~ JJj{(angiotensinogen, AOG) 'Ifo. 'f ~~~* (ang-

_Af;l 1111111&... • ,__ _ _ ~ • • 't'I'S

M'IIII:,u"u'mnt."lll~ ._ p s --.azMfJJII·

~••,.~·'rra .~.~n

'._II.H~·_U ..R::tT~ · .r ,. *'"M TAtUlChlAJLZ_·.L(,M 1_ _ 1

D e.t•• "M·~ IJl....... -".l_ • ..­i!Wipr .. t a.-.zMO l i!l=l •

&..~~.~~~.~.

SM.'''. {.-....l · · · ' i A...saa~·.··>..~....... . , ...1lZ. 1l••urEl $' ,*

I......l ... · .. , •( __l ;ZM '1Ibl

........9 Ie-,....al . 11II• h l .. nIk)

;tIIt;. •...,... 1 u.4l U

~·..... ·~.iiF..· ~

Ij!I'lD 'I'.r7~·

_ ·,tIIL ...it..... '.'_ ,M u ' r lJil • • " . .._ _..---_.__ _.._.._ _-----_._-=:iI,...__, _ .._ (u~. e......... lUi.... ,_ _-.U--.l · _ _ IU'-.l _......._ ,I ' ".,a_..... ' p._..__._UO!>l ,_ :d_-. l "'-.l ...

4._ I~l

rJ!Wi~IIU:IQQll\ft ' _,,-/IUjp;>"WIIl.Z - ' JUJUoIfta'aUMIlIDI;t- · Il :=AlJl ~1!

~'.I!•••z.~n ~..~TIik ' ~ttNM1lflC ' Z I!Il.....,·.- 11i 'fA '.....lOlllftli ~ ••-rt:bC

ft:'fl" · II~.ElI~ ·.lH:M!IIeIldll·..~&>.iit:

~A·.J.IIU_

....... f _".1: · IIS.lH.·a.attaa ' -... • •

Pi."'''~''- ' . _.. "

••;•••••••••

*ftom~E~mm~~ffiH.~.$.~~~

W:MJlj(AAiff~m ' ;1t$leptin ' adiponectin ' omentinWvisfatin ~JlM:1Jt:MJlj(AAi~fFm*-=r- ' rm resis­tin' TNF-a ' IL-6 W RBP4 J{rjJlM:{@:MJlj(AAi~fF

m*-=r-°

1m ' ~~I~~~~73'f'F~f~~~i~m21~IDJ§~h~M1E r:fbwcf!fJgl~~ r:fbJ'!ffa1(@~ J¥h* Jj]

fJg , ~flilj1fn.:MW;1t1tM~~~f!~UW~~iIi\ ' 1It1i7(~ffl'*PJfJg~~EI3::f[j::l]~~ft~f~*~¥ljmll1J~

§ i¥J 0 PJ r ~ ~t f.t alpha-lipoic acid, R-lipoicacid ' chromium ' biotin ' pycnogenol Wsilymarin

~2~~~~~ffl'*fF~~ (~~) 0

Wrt$M (lipoic acid) -~ff:(£ff sWR~~m!fo/.J ' ;1t$PJ R~m!fo/.Jm7(~HJ'!ff~!fo/.Jr5'r1~

*-=r- ' fE[~ R-lipoic acid ::f~~imHlIf§~. '~lIt:(£rmW~~L~PJ a-lipoic acid~1-t~ 0 :(£f,,!!~~*~mfF~m:MJlj(AAi,;1t~PJa1(@~~*~

fJg , ~-flJ'!1Jt~ft~ffl'* 0 iJJ!fo/.J~~f~9(a ' a­Wrt$M~M1EJ'!ff~~.~*~~~~'RmW

1fn.:M~.ormw~~m.,Wrt$MJ'!ffa1(@~~

*Jj]fJgW~1~§~J¥h*~1l1Jt't~ , g~J'!ffm~1fn.:M~fFmo~ff~~~~~i¥J~~~'~~YMM

W~~.~'~~~~J¥h*W1fn.:M~m~o

~

.a/l!:ffi~].I~~"'U

~.1t:

7.kmfiiEJJl~fi

MJle:~~

fflJl3(~

~

.~

N-Z.lt~*lIJ'tit~

Omega-3 ~:7f:::f@E!fOR~JI1j~

~~~~*Jj]1fg~~1ft~~*~lUfi:'11: ' it~PJJ:Jf!JEJfiJ.*I-@I;I:1,@~~~*~n~~*m'l1: ; ~1ft-=:~i:tnB~ ; ~~MzfflJ'l:1f~1ftJfiJ.Ii~~~JfiJ.m~J;t'$

~~~~*Jj]1fg~~1ftJfiJ.Ii-@l;l:

~1ftl1:ffi~linzlJ&~1r

MWJlin~lWt7.k1t~~z?}M

tll!JtHfJj]1fgffij.WJJfiJ.liz~t4:

~1ftJfiJ.Ii-@l;l:

~1ft~JIlJfiJ.1i ' ~~&JfiJ.Ii:lt1JU~JfiJ.R~fii

MJI e:fi-f-z7.k~'I1:.aJ'l:1f~~i!lt7J(1t~~IJ&~1r~1,@~~~*m'11~;!iHB~,l(nlG?) EGCG PJ~~~~*fil{~'I1:~iiiilizfIJffl~~1-t~

~ff,$-~1tM.z1WJmrtg~, i))\ff,$JfiJ.~fI~"'U ' J'l:1f~1ftJfiJ.~zfFffl

~ff,$&\mrm~fii ' PJ~1ft~JIlJfiJ.m ' tll!JtiWi~JJlR~mBIIMI!!!fM

~pfi-@lzlimBJ'l:1f~~Ii!*(p<j , iWiJfiJ.~ , JfiJ.R~fii~f\n!i@mF,,'Jm

-@llinlG?}Z M;fEJ'l:1f~~iiiiliilUgl:'11:

~~~~*rnmtt~-=:~i:tnB~-@I.;~~J'l:1fm~~~ffl,ffij~~~m!*

(p<j1tt~~

~1ft*~IIMI!!!I!I¥~1ft~JJlR~m BIIMI!!!fM~~~~*~ll.m'l1:

22

~!fo/.J* (biotin ) m*I~* B ~~- , ;1tm~~~~*::f PJ~i¥J !fo/.J. , ;1t~J'!ff~~J¥h*r5

'fi 0 ~!fo/.J*PJPJ~~liiJ:M ' )J3f~MWm~~M1-tr:

~Z-£1l9 0 ~!fo/.J* (2000 mg/day) W~ (600

•

mg/day) ~1#~m-~~fIl Ji ' J'!ff~1~1fn.:MWHbAlc (mJmM:~1fn.:M~n ~~f~~ ) ~~::m 'HJ'!ffa1(@1fn..lt$ 0 ~ (chromium ) m-fl~\rmll!fo/.J. ' J'!ff~~*~Jj]~ , ~.WJ*H1~~t1fn.

.L.~W~~o~~.~~~~lli~~~~~

~f,*!$W.Jlj(wqL~W\ ' f9ljtlo~p.xIfnmH!rtti1JoW

iJiJ.if~'r1~1ft 0 jUtlfJlj(wq,"1!i ' ~7(M1E1000 mg L~~1lTa1!:~iJiJ.if~'11: 0

kI~/IVffim~~~ (fibre/starch blockers ) 1lT~1ft~;ffiWIf~LI!&~1l: 0 JJ:t1tl- ' rE'JklW1ft.1tf(!jo/jJ'!1'f~1ftIfn. ' H?Ma~WIfnH~1f-2i;' 0

~H:if. (pycnogenol ) ~ft£~~7Jf#lJ;ft,L}WEl

pJT~~LP.X0 ' ~m7(~L1Jt~1t!jo/j , J'!1'f1!lJfIi'j1:1 glucosidase 75'11: ' ffijMWJ.~W~7k1t~!jo/jL0Mo~H:if.~J'!1'f~~~~Ifn.W~~~~Ifn

.Ltti1JO 0 ImWutfJN!Ho ' .Jlj(wq}!1!i~7(.~50 mg L~H:if.jj=:fIOOJi ' Zf~1lT~1ft 1O%~~IfnIf-2i;' , ffij~7(.~ 200 mg~lj1lT~1ft 13%L~

~IfnIf-2iIio

7kmfij (silymarin ) mr:p~*fij (Silybum

marianum) PJT~~ffijf~L1Jt~1tp.x0 ' ~J'!1'ffJl!

ftJffJJiiJj]ffgW~lmIfnIf-2iIi 0 -flOO~jj-:$i¥Jutf

J"G1~lli ' ~-=Y.Jlj(wq}!1!i~7(.~ 600 mgL7kmfij , 1lTj;J~1ft 13-15 %LIfnIf-2iIi ' tOk~1ftJlj(

.WHbA1cL-2i;' 0 ~ft!!fJ~'11:p.x0l\!t1-t~~f~

!$Lm~~'~1'f~.Lft*'M~~m,~

f! ' liJjiiE:! ' *i;f- , MH3(M ' ~ , .~ , N-Zftl

~*ID't~M ' omega-3 ~n~iBIfOH~JJ1JM ' ftli!jo/jI!'!IIWWliTriMm~J'!1'f~[I"t]f1l[1tL1!IJfliljfFffl 0

*~§ L ' ~B1:757k~LfJI!ft ' ~1tfO~.m~f(L.~,&ffijp.xm~~X~wqi¥J~~'~

r:p1-t~~f~!$JIPmH~H~pJTfrr1:Lt§~M~wq 0 ~ffij

~~i¥J~mM.~Lf(!jo/j,~p.xmm~X~wqi¥J

lifiJ.o JJ:t1tl- ' ~E8fJffg 'I1:p.x0L.~ , *jj~'jm~~~~~!$L~1: ' ~~**~~i¥J~~~~

L-o

1. Challem, J. 2007. Metabolic syndrome: natural solutions

for a worldwide health problem. FUNCTIONAL IN­

GREDIENTS. httpl:lt1tNww.tilnctionalingredientsmag.

com/funag/articleDisplay.asp? strArticleId=1433

2. Deen, D. 2004. Metabolic syndrome: time for action.

American Family Physician 69: 2875-2882.

3. Ford, E. S., Giles, W. H. and Dietz, W. H. 2002. Preva­

lence of the metabolic syndrome among US adults: fmd­

ings from the third National Health and Nutrition Exam­

ination Survey. The Journal ofAmerican Medical Associ­

ation 287: 356-359.

4. International Diabetes Federation, 2006. The IDF Con­

sensus worldwide defmition of the metabolic syndrome.

Brussels, Belgium: International Diabetes Federation.

5. Perel, P., Langenberg, C., Ferrie, J., Moser, K., Brunner,

E. and Marmot, M. 2006. Household wealth and the meta­

bolic syndrome in the Whitehall II study. Diabetes Care

29: 2694-2700.

6. Sowers, J. R. 2003. Obesity as a cardiovascular risk fac­

tor. The American Journal ofMedicine 115: 37S-41S.

7. World Health Organization, 1999. Definition, diagnosis

and classification of diabetes mellitus and its complica­

tions: report of a WHO Consultation. Part 1: diagnosis

and classification of diabetes mellitus. Geneva, Switz­

erland: World Health Organization.

DDo:>

23